Phaseline

Companies › Soleno Therapeutics

Soleno Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Diazoxide
Potassium channel, inwardly rectifying, subfamily J, member 11 opener; Potassium channel, inwardly rectifying, subfamily J, member 8 opener
Ion channelsPhase 3Prader-Willi Syndrome; Diabetes Mellitus; Hyperinsulinemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05701774DiazoxidePhase 3Prader-Willi SyndromeOtherJan 2026
NCT03540758DiazoxidePhase 2Diabetes MellitusMetabolic and endocrineApr 2027
NCT07403604DiazoxidePhase 1HyperinsulinemiaMetabolic and endocrineSep 2029

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

LXO Ireland Biotechnology Institute IMASD Energenesis Biomedical Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.